$ATYR
aTyr Pharma Inc

2021 Q1 Form 10-Q Financial Statement

#000156459021028014 Filed on May 14, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $8.065M
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.690M $2.590M
YoY Change 3.86% 2.37%
% of Gross Profit
Research & Development $4.520M $3.620M
YoY Change 24.86% 8.06%
% of Gross Profit
Depreciation & Amortization $121.0K $157.0K
YoY Change -22.93% -5.99%
% of Gross Profit
Operating Expenses $7.200M $6.206M
YoY Change 16.02% 5.6%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $47.00K -$110.0K
YoY Change -142.73% -57.69%
Pretax Income -$7.160M $1.750M
YoY Change -509.14% -128.5%
Income Tax
% Of Pretax Income
Net Earnings -$7.155M $1.752M
YoY Change -508.39% -128.55%
Net Earnings / Revenue 21.72%
Basic Earnings Per Share -$0.51 $0.25
Diluted Earnings Per Share -$0.51 $0.25
COMMON SHARES
Basic Shares Outstanding 14.10M 6.882M
Diluted Shares Outstanding 14.10M 6.885M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.64M $49.80M
YoY Change 1.68% 15.81%
Cash & Equivalents $12.59M $39.45M
Short-Term Investments $38.05M $10.40M
Other Short-Term Assets $1.400M $500.0K
YoY Change 180.0% -54.55%
Inventory
Prepaid Expenses $1.408M
Receivables
Other Receivables $89.00K
Total Short-Term Assets $52.10M $50.40M
YoY Change 3.37% 12.75%
LONG-TERM ASSETS
Property, Plant & Equipment $2.800M $3.900M
YoY Change -28.21% -22.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $234.0K $100.0K
YoY Change 134.0% -50.0%
Total Long-Term Assets $3.028M $4.000M
YoY Change -24.3% -23.08%
TOTAL ASSETS
Total Short-Term Assets $52.10M $50.40M
Total Long-Term Assets $3.028M $4.000M
Total Assets $55.13M $54.40M
YoY Change 1.34% 9.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.161M $700.0K
YoY Change 65.86% -12.5%
Accrued Expenses $2.400M $2.700M
YoY Change -11.11% 42.11%
Deferred Revenue $143.0K
YoY Change -77.3%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $6.866M
YoY Change -11.97%
Total Short-Term Liabilities $4.500M $10.45M
YoY Change -56.92% -6.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.100M $2.000M
YoY Change -45.0% -28.57%
Total Long-Term Liabilities $1.100M $2.000M
YoY Change -45.0% -78.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.500M $10.45M
Total Long-Term Liabilities $1.100M $2.000M
Total Liabilities $5.400M $12.30M
YoY Change -56.1% -39.71%
SHAREHOLDERS EQUITY
Retained Earnings -$345.7M
YoY Change
Common Stock $16.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.70M $42.10M
YoY Change
Total Liabilities & Shareholders Equity $55.13M $54.45M
YoY Change 1.25% 9.11%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$7.155M $1.752M
YoY Change -508.39% -128.55%
Depreciation, Depletion And Amortization $121.0K $157.0K
YoY Change -22.93% -5.99%
Cash From Operating Activities -$5.827M $2.058M
YoY Change -383.14% -134.17%
INVESTING ACTIVITIES
Capital Expenditures $17.00K $166.0K
YoY Change -89.76% 1560.0%
Acquisitions
YoY Change
Other Investing Activities -$23.38M $11.57M
YoY Change -302.07% -445.37%
Cash From Investing Activities -$23.40M $11.41M
YoY Change -305.11% -439.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.86M 16.78M
YoY Change 48.14% -2810.66%
NET CHANGE
Cash From Operating Activities -5.827M 2.058M
Cash From Investing Activities -23.40M 11.41M
Cash From Financing Activities 24.86M 16.78M
Net Change In Cash -4.365M 30.24M
YoY Change -114.43% -402.52%
FREE CASH FLOW
Cash From Operating Activities -$5.827M $2.058M
Capital Expenditures $17.00K $166.0K
Free Cash Flow -$5.844M $1.892M
YoY Change -408.88% -131.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2400000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
861000
CY2021Q1 dei City Area Code
CityAreaCode
858
CY2021Q1 us-gaap Assets
Assets
55128000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12587000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1886000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
35531000
CY2021Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
89000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
899000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1378000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2083000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
234000
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16064643
CY2020Q4 us-gaap Assets
Assets
38726000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3572000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
213000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1161000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1431000
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
731-8389
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
890000
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38050000
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2039000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16011385
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1408000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1803000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8065000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2686000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
6206000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
47000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-7155000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4000
CY2020Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14103783
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14103783
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6884797
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021Q1 dei Entity File Number
EntityFileNumber
001-37378
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3435077
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3545 John Hopkins Court
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite #250
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21425000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11018954
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
395422000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-57000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345679000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
49702000
CY2021Q1 us-gaap Minority Interest
MinorityInterest
-170000
CY2020Q4 us-gaap Minority Interest
MinorityInterest
-166000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
49532000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31484000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55128000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38726000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21425000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16011385
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11018954
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
121000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
360000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
423000
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6881791
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2020Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1739000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-7169000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-4000
CY2021Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
9621000
CY2021Q1 life Issuance Of Common Stock From Committed Purchase Agreement Net Of Offering Costs
IssuanceOfCommonStockFromCommittedPurchaseAgreementNetOfOfferingCosts
15236000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
360000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
21026000
CY2020Q1 life Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
18779000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
41967000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
157000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
423000
CY2020Q1 us-gaap Accretion Expense
AccretionExpense
129000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-51000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
24000
CY2021Q1 life Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
176000
CY2020Q1 life Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
201000
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6000
CY2021Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1950000
CY2020Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-48000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-395000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-188000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1521000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-578000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-65000
CY2021Q1 life Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-204000
CY2020Q1 life Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-179000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5827000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2058000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
166000
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
25678000
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
3081000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
2300000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
14650000
CY2020Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23395000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11406000
CY2021Q1 life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
9621000
CY2021Q1 life Proceeds From Issuance Of Common Stock Through Registered Direct Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughRegisteredDirectOfferingNetOfOfferingCosts
15236000
CY2020Q1 life Proceeds From Issuance Of Common Stock Through Underwritten Follow On Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenFollowOnOfferingNetOfOfferingCosts
18779000
CY2020Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
2000000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24857000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16779000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4365000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30243000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16952000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9210000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12587000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39453000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure for these items in our condensed consolidated financial statements and accompanying notes. The most significant estimates in our condensed consolidated financial statements relate to the fair value of equity issuances and awards, clinical trial and research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p>
CY2021Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. The reclassifications were not material to the condensed consolidated financial statements.</p>
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
38050000
CY2021Q1 life Cash And Cash Equivalents And Available For Sale Investments
CashAndCashEquivalentsAndAvailableForSaleInvestments
50600000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
913668
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
502004
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38057000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
14730000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
14737000
CY2020Q1 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
15
CY2020Q1 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
25
CY2020Q1 life Upfront Payment Received
UpfrontPaymentReceived
8000000
CY2021Q1 life Milestone Payment Received
MilestonePaymentReceived
2000000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
776000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1062000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
404000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
207000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2035000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1050772
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
576534
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
326456
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
12184
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
890806
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.33
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.52
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
25.47
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.49

Files In Submission

Name View Source Status
0001564590-21-028014-index-headers.html Edgar Link pending
0001564590-21-028014-index.html Edgar Link pending
0001564590-21-028014.txt Edgar Link pending
0001564590-21-028014-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
life-10q_20210331.htm Edgar Link pending
life-20210331.xml Edgar Link completed
life-20210331.xsd Edgar Link pending
life-20210331_cal.xml Edgar Link unprocessable
life-20210331_def.xml Edgar Link unprocessable
life-20210331_lab.xml Edgar Link unprocessable
life-20210331_pre.xml Edgar Link unprocessable
life-ex311_6.htm Edgar Link pending
life-ex312_10.htm Edgar Link pending
life-ex321_7.htm Edgar Link pending
life-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending